September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Metformin reduces diabetes-related inflammatory molecules in human vitreous and retinal vascular endothelial cells
Author Affiliations & Notes
  • Yue Li
    Ophthalmology, Henry Ford Health System, Detroit, Michigan, United States
  • Shawn Gappy
    Ophthalmology, Henry Ford Health System, Detroit, Michigan, United States
  • Xiuli Liu
    Ophthalmology, Henry Ford Health System, Detroit, Michigan, United States
  • Therese Sassalos
    Ophthalmology, Henry Ford Health System, Detroit, Michigan, United States
  • Paul A Edwards
    Ophthalmology, Henry Ford Health System, Detroit, Michigan, United States
  • Hua Gao
    Ophthalmology, Henry Ford Health System, Detroit, Michigan, United States
  • Xiaoxi Qiao
    Ophthalmology, Henry Ford Health System, Detroit, Michigan, United States
  • Footnotes
    Commercial Relationships   Yue Li, None; Shawn Gappy, None; Xiuli Liu, None; Therese Sassalos, None; Paul Edwards, None; Hua Gao, None; Xiaoxi Qiao, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 6346. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Yue Li, Shawn Gappy, Xiuli Liu, Therese Sassalos, Paul A Edwards, Hua Gao, Xiaoxi Qiao; Metformin reduces diabetes-related inflammatory molecules in human vitreous and retinal vascular endothelial cells. Invest. Ophthalmol. Vis. Sci. 2016;57(12):6346.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Inflammation plays a prominent role in the pathogenesis of diabetic retinopathy (DR). We have reported that metformin treatment is associated with substantially reduced severity of DR in patients, and significant anti-inflammatory action in animal models. The purpose of this study was to examine whether metformin affects the levels of inflammatory cytokines and chemokines in the vitreous of DR patients, and whether metformin specifically affects the diabetes related inflammatory molecules in human retinal vascular endothelial cell cultures.

Methods : Patients with type 2 diabetes for more than 15 years with or without metformin treatment for at least 5 years prior to the onset of DR were included respectively as metformin treatment group or control group. Undiluted core vitreous biopsies were collected for analysis of a panel of inflammatory and immune molecules using a Human Cytokine Array. Primary cultured human retinal vascular endothelial cells (hRVECs) were challenged by high glucose with or without metformin co-treatment. The expression of ICAM-1 and phosphorylated NF-κB in hRVECs were measured by western blot. The production of TNFα and IL-8 by the cell were determined by ELISA.

Results : Our data revealed that metformin treatment significantly reduced the levels of multiple key molecules crucial for the inflammatory and immune responses in the vitreous of DR patients, including ICAM-1, MCP-1, Serpin E1, CXCL12, CXCL10, MIF, IL-6, and C5/C5a. High glucose exposure remarkably elevated the expression of ICAM-1 (p〈 0.01) and pNF-κB (p〈 0.05) in hRVECs; as well as the production of TNFα (p〈 0.001) and IL-8 (p〈 0.05) by hRVECs. Metformin completely reversed the up-regulation of ICAM-1 and pNF-κB induced by high glucose to a level comparable to the normal control. Metformin also markedly reduced the levels of TNFα and IL-8 elevated by high glucose in hRVECs (both p〈 0.05). The effects of metformin on hRVECs were at least partially blocked by compound C, an inhibitor of AMP-activated protein kinase.

Conclusions : Our results confirm that metformin directly and effectively suppresses the inflammatory and immune responses in the pathogenesis of diabetic retinopathy. Such a strong anti-inflammatory action of metformin could be a major mechanism underlying its vascular protective effect.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×